Abstract
Small non-cleaved cell lymphoma is one of the most rapidly growing malignancies and in children is highly curable. However, in adults, the disease is disseminated in approximately one half of the patients, and with standard chemotherapy used for lymphoma, is less curable than it is in children, especially in patients presenting with bone marrow involvement. However, recent developments in clinical management using intensive dose therapy for this disease have improved the eventual outcome for these patients. This review focuses on some of these improvements.
References
Sep 23, 1976·The New England Journal of Medicine·R B MannC W Berard
Mar 11, 1975·The American Journal of Medicine·J C ArseneauV T DeVita
Mar 1, 1991·The American Journal of Medicine·D J StrausB D Clarkson
Jan 1, 1989·Medical and Pediatric Oncology·J L FinlayS Frierdich
Feb 1, 1987·British Journal of Haematology·T PhilipF Chauvin
Mar 15, 1987·Cancer·D R KellyC W Berard
May 11, 1974·British Medical Journal·I T MagrathN Harrison
Sep 15, 1983·Cancer·A M LevineD I Feinstein
Apr 1, 1981·AJR. American Journal of Roentgenology·A G KrudyR Spiegel
May 1, 1982·Cancer·T M GroganH S Kaplan
Nov 15, 1982·Cancer·J R MiliauskasV T DeVita
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F B HagemeisterF Cabanillas
Mar 1, 1961·Cancer·D BURKITT, G T O'CONOR